Academic Journal
Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity
| العنوان: | Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity |
|---|---|
| المؤلفون: | Zile, Michael R., Borlaug, Barry A., Kramer, Christopher M., Baum, Seth J., Litwin, Sheldon E., Menon, Venu, Ou, Yang, Weerakkody, Govinda J., Hurt, Karla C., Kanu, Chisom, Murakami, Masahiro, Packer, Milton |
| المساهمون: | Eli Lilly and Company |
| المصدر: | Circulation ; ISSN 0009-7322 1524-4539 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health) |
| سنة النشر: | 2024 |
| الوصف: | Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical endpoints, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden in these patients. Methods: 731 patients in class II-IV heart failure, ejection fraction ≥50%, and body mass index ≥30 kg/m 2 were randomized(double-blind) to tirzepatide(titrated up to 15mg subcutaneously weekly)(n=364) or placebo(n=367), added to background therapy for a median of 104 weeks (Q1=66, Q3=126 weeks). Primary endpoints: tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score(KCCQ-CSS). The current expanded analysis included sensitivity analyses of the primary endpoints, 6-minute walk distance(6MWD), EQ-5D-5L health state index, Patient Global Impression of Severity Overall Health(PGIS), NYHA class, use of heart failure medications, and a hierarchical composite based on all-cause death, worsening heart failure, and 52-week changes in KCCQ-CSS and 6MWD. Results: Patients were aged 65.2±10.7, 53.8%(n=393) were female; BMI 38.2±6.7kg/m 2 , KCCQ-CSS 53.5±18.5, 6MWD 302.8±81.7meters, and 53%(n=388) had a worsening heart failure event in the prior 12 months. Compared with placebo, tirzepatide produced a consistent beneficial effect across all composites of death and worsening heart failure events, analyzed as time-to-first-event (hazard ratios 0.41-0.67). At 52 weeks, tirzepatide increased KCCQ-CSS 6.9 points (95%CI, 3.3, 10.6, P<0.001), 6MWD 18.3 meters (95%CI, 9.9, 26.7, P<0.001) and EQ-5D-5L 0.06 (95%CI, 0.03, 0.09, P<0.001). The tirzepatide group shifted to a more favorable PGIS ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1161/circulationaha.124.072679 |
| DOI: | 10.1161/CIRCULATIONAHA.124.072679 |
| الاتاحة: | http://dx.doi.org/10.1161/circulationaha.124.072679 https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.124.072679 |
| رقم الانضمام: | edsbas.A28BC7AB |
| قاعدة البيانات: | BASE |
| DOI: | 10.1161/circulationaha.124.072679 |
|---|